Gilead, the manufacturer of remdesivir, an experimental drug for the treatment of COVID-19, is donating 607,000 vials of the drug over the next six weeks.  This is enough to treat about 78,000 patients.

The government will deliver the drug to state health departments and the drug will be distributed to hospitals based on need.  HHS stated patients eligible to receive remdesivir are patients on ventilators or mechanized ventilation.

Healthcare providers interested in using this experimental drug should contact their local state health department.